PTC Therapeutics, Inc.


PTC Therapeutics is a global biopharmaceutical company dedicated to transforming lives by developing innovative therapies for people living with rare diseases. With 25 years of scientific expertise, the company focuses on research platforms such as splicing and inflammation & ferroptosis to create groundbreaking treatments. PTC is committed to patient-centric approaches, clinical research, and making a positive impact on communities and the environment.

Industries

biotechnology
health-care
therapeutics

Nr. of Employees

Very Large (1000+)

PTC Therapeutics, Inc.

South Plainfield, New Jersey, United States, North America


Products

Sephience™ (sepiapterin)

A treatment for phenylketonuria (PKU) granted marketing authorization in Europe for children and adults.

Translarna™ (ataluren)

An approved medicine for Duchenne muscular dystrophy caused by a nonsense mutation.

Emflaza® (deflazacort)

An approved treatment for Duchenne muscular dystrophy.


Services

Healthcare Provider Resources

Supporting healthcare providers with scientific information and resources to improve patient care.

Patient & Caregiver Resources

Providing support and educational materials for patients and families living with rare diseases.

Investor Relations Support

Offering information and updates for investors interested in PTC's developments.

Clinical Trials

Conducting and supporting clinical research to develop new treatments for rare diseases.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.